Fund Twenty8
VC Fund
Cambridge, United Kingdom
Fund Twenty8 is a VC fund in Cambridge focused on Health Care and Medical. Smart Beta for Early stage investing - Fund Twenty8The fund is the first passive EIS fund for early stage investments. It will deliver a multi-sector and large portfolio for investors.They believe Fund Twenty8 addresses two key areas currently underserved by the EIS fund market. A lack of sector diversification within a fund and a failure tobenefit from a wide portfolio approach investing. Traditional early stage funds usually focus on a single sector (exposing investors to sector-specific risks) and usually only invest in 5 to 8 investments per fund. They feel there is a need in the market for a multi-sector and large portfolio fund for early stage investments. That's why they created Fund Twenty8.Fund Twenty8 offers investors access to a diversified portfolio with at least 28 investments per fund and across multiple sectors.
- Total investments:
- 34
- Last investment:
- Lead investor:
- 3%
- Fund size:
- $5.9M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Fund Twenty8 invests in
Stages Fund Twenty8 invests in
Countries Fund Twenty8 invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $508k–$1.9M
- Series A
- $2.3M–$3.4M
- Venture - Series Unknown
- $414k–$3.1M
Investment Focus
Industry
- Health Care 10 (29%)
- Medical 8 (24%)
- Biotechnology 5 (15%)
- Medical Device 5 (15%)
- Software 3 (9%)
Stage
- Seed 17 (50%)
- Venture - Series Unknown 9 (26%)
- Series A 2 (6%)
- Series B 2 (6%)
- Angel 1 (3%)
Country
- United Kingdom 32 (94%)
- United States 1 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
| CEO | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| We are Liopa. We were incorporated in 2015 to commercialise more than 15 years of PhD research at QUB in the field of speech and image processing. Using this deep knowledge, we developed an automated lipreading solution. Our technology – rooted in machine learning and AI – can decipher what a person is saying from their lip movements alone.Liopais the first company to release commercially available VSR (Visual Speech Recognition) technology, with the first application being our SRAVI app (www.sravi.ai). SRAVI is a simple lipreading application that requires just a smartphone. It is bringing a voice to the voiceless. With SRAVI, we help patients who have lost the ability to speak, to communicate with their loved ones & carers. SRAVI is deployed onto a smartphone, and when pointed towards the patient, the app analyses their lip movements to decipher what they are trying to say. SRAVI is being trialled in Intensive Care units within the NHS. | $589.6K / Seed / Apr 08, 2019 | ||
| SupaPass is an all-in-one website and app creation platform for any business to launch its own website and apps. SupaPass allows anyone to create beautiful and powerful, payment-ready, all-in-one content website and mobile apps instantly without any technical knowledge.With millions of individuals and businesses globally needing a launch-ready,affordable content driven website and app, SupaPass is an innovative white-label platform that allows clients to retain 100% of sales and full ownership of customer data at the touch of a button. It offers more cost-effective and intuitive designs to make content such as podcasts, video, audio and streaming channels more manageable, it is over 10 times faster and cheaper than custom-built solutions.With SupaPass’s technology clients are able to keep their own brand front and control how they interact with their customers. With a content layout similar to Netflix and Prime, SupaPass gives clients the tools they need to have everything in one place to grow their business online. It services a wide range of sectors and verticals including Podcasting, Fitness, and Wellbeing, TV and Film, Archives, Membership Organisations, Music, Sport, Charities, Conferences, and Consultancies.SupaPass was founded in 2011. | $507.6K / Seed / Dec 30, 2018 | ||
| Lightpoint Medical is an early-stage medical device company founded in 2012. The company is developing a breakthrough intraoperative imaging technology called Cerenkov Luminescence Imaging (CLI). CLI has the potential to detect cancer in real-time during surgery, and thereby reduce the likelihood of cancer recurrence and the need for reoperation. | $6.4M / Series B / Dec 06, 2018 | ||
| Pertinax Pharma Ltd. is a patent-protected, sustained release technology for chlorhexidine, a common antiseptic. Pertinax have developed an innovative range of controlled release antimicrobial materials with applications across many industries and sectors. | $1.1M / Venture - Series Unknown / Oct 11, 2018 | ||
| MGB Biopharma Limited is a biopharmaceutical company established to develop a completely new class of anti-infective medicines based upon compounds which are DNA Minor Groove Binders (MGB)The company has an exceptionally experienced team from both pharma and biotech sectors and is dedicating its focus initially to the development of smallmolecules with specific antibacterial efffects against resistant bacteriaBy selecting a new class of antibacterial, the company believes the novel mode of action should prove to be very potent against bacteria as these target organisms will lack any inherent resistance, unlike that typically facing new drugs which are the result of modifications from existing classes of drugs used to treat bacterial infection | $1.7M / Venture - Series Unknown / Sep 14, 2018 | ||
| infloAi is a London-based software company building proprietary AI technology to make content creation simple, fast and affordable for any business.Currently, content teams are forced to stitch together multiple solutions, use expensive agencies or they simply cannot produce the level of engaging content required - turning their back on valuablerevenue. infloAi changes that: our technology helps streamline the process through clever automation - making it simple to produce content that will increase engagement and revenues.We’re now looking to grow our core team before raising Series A in Q4 2019. | $848.6K / Seed / Sep 04, 2018 | ||
| Gelmetix develops multiple grades of polymer gel to provide affordable non-invasive alternatives to surgery for conditions like Chronic Lower Back pain and Osteoarthritis. Their lead product is a hydrogel for nucleus pulposus augmentation to relieve pain in patients suffering from Chronic Low Back Pain. Gelmetix is a diversified therapeuticbiomaterials company incorporated in the UK. It has offices in London, Paris, and Manchester. | $1.6M / Series B / Sep 01, 2018 | ||
| Naked Energy has developed an innovative hybrid solar technology generating combined heat and power.The versatile, modular design of Virtu® places crystalline photovoltaic cells in an evacuated solar thermal collector. For any given area more of the sun’s energy is converted into heat and electricity (80% of the 1000W/m2 available) thanksto the patented heat transfer mechanism.Thermal and electrical outputs are optimized irrespective of geographic or climatic conditions. With the isothermally cooled PV cells protected from the environment, Virtu® is especially suited to harsh high-insolation markets.Naked Energy is in the final stages of preparing for commercial launch to address global applications for domestic, commercial and industrial customers. Virtu® is both disruptive and scalable. | $1.5M / Venture - Series Unknown / Aug 23, 2018 | ||
| Mayku provides a platform for creators to access machines, materials, and services in order to create their own products. FormBox, Mayku's product, is a desktop-sized vacuum former that allows users to easily create a mold or model of their choice at a low cost. Mayku's other product, the Multiplier, is a machine that uses pressureforming to enable rapid production scaling. Mayku enables the manufacture of products locally, quickly, and affordably by providing creators with the hardware, raw materials, and software required to produce a wide range of items. It accelerates the global shift to local manufacturing. | $598K / Seed / May 31, 2018 | ||
| Arcis Biotechnology is focused on providing fast and convenient nucleic acid sample prep solutions. Obtaining genetic material from biological samples is a critical step which is often a time consuming and inefficient process. In less than 3 minutes with no prior sample preparation the Arcis DNA Prep range of products allow users to quickly andconveniently go from cellular material to downstream nucleic acid investigation without the need for traditional isolation or purification. The process requires no laboratory equipment and requires as little as 30µl of blood as a starting material. Arcis DNA products can be used on many different samples containing DNA including whole blood, plasma, urine, buccal swabs, and hair follicles . | $1.6M / Equity Crowdfunding / Apr 16, 2018 | ||
| See all 34 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Fund Twenty8 invest in?
Fund Twenty8 invests primarily in Health Care, Medical and Biotechnology startups, most often at Seed and Venture - Series Unknown stage. Most of the 34 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Fund Twenty8's check size?
Fund Twenty8 typically joins rounds of $508k–$1.9M at Seed, $2.3M–$3.4M at Series A and $414k–$3.1M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Fund Twenty8 participates in.
How do I contact Fund Twenty8?
Public channels for Fund Twenty8 include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Fund Twenty8?
The team at Fund Twenty8 includes Goncalo de Vasconcelos (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
